Mediwatch raises £347K to advance global growth strategies
This article was originally published in Clinica
UK urology diagnostics specialist Mediwatch has raised £347,440 ($582, 600) through the placement of over six million new shares on the London Stock Exchange's alternative investment market, where the firm is listed. The proceeds will be used for working capital and to help realise four opportunities that the company has identified to support its international growth. These opportunities include creating a joint venture with an international partner, sharing technology and pursuing a common marketing campaign; assessing the use of Mediwatch's bioassays with another international partner; promoting its prostate-specific antigen (PSA) system for assessing urological problems alongside a partner's proprietary point-of-care system; and in-licensing and researching the use of a bladder cancer marker with the Mediwatch BioScan reader.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.